One way or another, it is an important time in the Alzheimer’s disease space. Two potential disease altering therapies are set to divulge Phase III results that will answer important questions about the course of the illness, whether they are successful or not, and a promising cognition booster may get the Phase II readout it needs to head into a pivotal trial.

Lilly’s Avid has gained approval for its imaging agent Amyvid, a new tool in the Alzheimer’s disease diagnosis arsenal.

Sponsors and contract research organizations expressed cautious optimism about FDA's adoption of some of the recommendations of the Alzheimer's Association Research Roundtable Workgroup, but the agency isn't specifying which recommendations it is accepting.